SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST community is rallying around the token's unique ecosystem, which focuses on generating passive income through its appreciating stablecoin, FUSD. Investors are highlighting this yield-focused model as a sustainable alternative to traditional stablecoins, fueling anticipation for future growth and platform developments.

WorldFinancial

World Liberty Financial ($WLFI) is facing intense scrutiny and volatility following reports of a congressional investigation into its foreign capital dealings and a high-value stake acquisition by UAE-linked investors. The community remains sharply divided, with supporters viewing recent price dips as a strategic buying opportunity tied to potential institutional adoption, while critics continue to label the project as a high-risk venture and a vehicle for self-enrichment.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention through a combination of technical strength, whale accumulation, and anticipation of upcoming network upgrades that promise increased programmability. The community is actively debating its potential to decouple from Bitcoin and reclaim its historical role as a peer-to-peer electronic cash system, with many investors maintaining a bullish long-term outlook.

VanEck ETF Trust - VanEck Agribusiness ETF

VanEck Agribusiness ETF

Investors are increasingly rotating into the agribusiness sector, driving fresh inflows into $MOO as the community anticipates potential food supply constraints and favorable shifts in global agricultural demand. Market participants are actively comparing the VanEck Agribusiness ETF to direct commodity futures, highlighting its appeal as an equity-based defensive play for those seeking structural growth outside of the tech sector.

RAWW MILK COIN

Investors are rallying behind RAWW, a memecoin that has sustained its community for over a year by building an ecosystem of webtoons, games, and music rather than relying on short-term hype. The project is trending as supporters contrast its consistent, unconventional content with traditional market volatility, framing their commitment to the token as a lifestyle-driven "milk-pilled" movement.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as community members weigh the asset's long-term utility in enterprise banking and interoperability against ongoing frustration regarding its sluggish price action and correlation with broader market volatility. Investors remain divided, with many aggressively accumulating at current levels in anticipation of a supply shock, while others express exhaustion over the extended consolidation phase.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is trending as investors debate the impact of the Digital Asset Market Clarity Act, which could permanently codify the token as a digital commodity and potentially unlock long-term institutional interest. While the community remains divided between speculative hopes of burning supply to reach higher price levels and frustration over extended periods of consolidation, many long-term holders continue to view current price action as a strategic accumulation zone.

Banco de Chile SA engages in the provision of banking services. It operates through the following segments: Retail Banking, Wholesale Banking, Treasury, and Money Markets, and Subsidiaries. The Retail Banking segment consists of consumer loans, commercial loans, checking accounts, credit cards, credit lines, and mortgage loans. The Wholesale Banking segment includes corporate clients and large companies where the product offering focuses on commercial loans, checking accounts and liquidity management services, debt instruments, foreign trade, derivative contracts, and leases. The Treasury and Money Markets segment comprises securities portfolio, derivatives positions, and currency trading. The Subsidiaries segment corresponds to companies and corporations controlled by the bank. The company was founded on October 28, 1893 and is headquartered in Santiago, Chile.

Banco de Chile - ADR

Banco de Chile

Banco de Chile is currently experiencing heightened investor attention, with the community actively discussing whale accumulation patterns and the bank's role as a defensive, income-generating asset. Traders are closely monitoring key chart levels and technical indicators as the stock maintains strong support despite broader market volatility.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy Corp. (VLO) is attracting significant attention as investors weigh institutional accumulation against sector-wide concerns about refining margins and energy demand. The stock remains a focal point for traders navigating geopolitical volatility and the shifting landscape of global oil logistics.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is experiencing significant community debate as investors anticipate the Goliath mainnet launch, with many users focused on potential real-world utility and payment infrastructure integration. While some long-term holders remain bullish on the project's roadmap, others are actively criticizing the token's price action and expressing skepticism regarding team transparency and historical market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?

Investors need to pay close attention to AKBA stock based on the movements in the options market lately. 

Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference

Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company's near- and mid-term priorities at the Leerink Partners Global Healthcare Conference, emphasizing the commercialization of its anemia...

Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John Butler purchased 69,270 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was acquired at an...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 31,207,330 shares, a...

Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA

Citigroup Inc. boosted its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 1,324.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold

Wall Street Zen cut shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Equity

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.


Akebia Therapeutics Q4 Earnings Call Highlights

Akebia Therapeutics (NASDAQ:AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic...

Akebia Therapeutics, Inc. Q4 Loss Decreases

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) revealed Loss for fourth quarter of -$12.24 million...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.03	--	--	N/A
Q4 '25	-$0.04	-$0.05	-38.89%	MISSED
Q3 '25	-$0.01	$0.00	100.00%	BEAT
Q2 '25	-$0.02	$0.00	100.00%	BEAT
Q1 '25	-$0.04	$0.03	178.95%	BEAT

AKBA
Akebia Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest AKBA News

AKBAAkebia Therapeutics Inc.